Andrew S Dixon
Overview
Explore the profile of Andrew S Dixon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
900
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim S, Dixon A, Owen S
Acta Biomater
. 2021 Sep;
135:225-233.
PMID: 34496282
Over 30,000 protein-protein interactions with pathological implications have been identified; yet, discovering and investigating drugs that target these specific interactions is greatly limited by the inability to monitor native protein-protein...
2.
Kim S, Dixon A, Adamovich P, Robinson P, Owen S
ACS Sens
. 2021 May;
6(5):1807-1814.
PMID: 34010570
Anti-TNF therapeutics bind and sequester tumor necrosis factor (TNF) to prevent downstream signaling and are clinically important in the treatment of several autoimmune diseases. Effective treatment with these drugs requires...
3.
Christopher Radford D, Yang J, Doan M, Li L, Dixon A, Owen S, et al.
J Control Release
. 2020 Jan;
319:285-299.
PMID: 31899273
Incorporating targeting moieties that recognize cancer-specific cellular markers can enhance specificity of anticancer nanomedicines. The HER2 receptor is overexpressed on numerous cancers, making it an attractive target. However, unlike many...
4.
Kim S, Hatch S, Dixon A, Owen S
Biotechnol Bioeng
. 2019 Apr;
116(7):1575-1583.
PMID: 30934115
Expressing, isolating, and characterizing recombinant proteins is crucial to many disciplines within the biological sciences. Different molecular tagging technologies have been developed to enable each individual step of protein production,...
5.
Schwinn M, Machleidt T, Zimmerman K, Eggers C, Dixon A, Hurst R, et al.
ACS Chem Biol
. 2017 Sep;
13(2):467-474.
PMID: 28892606
Intracellular signaling pathways are mediated by changes in protein abundance and post-translational modifications. A common approach for investigating signaling mechanisms and the effects induced by synthetic compounds is through overexpression...
6.
Dixon A, Kim S, Baumgartner B, Krippner S, Owen S
Sci Rep
. 2017 Aug;
7(1):8186.
PMID: 28811487
Protein-fragment complementation is a valuable tool for monitoring protein interactions. In complementation assays, the reporter fragments are directly fused to the interacting proteins, eliminating the possibility of monitoring native interactions....
7.
NanoLuc Complementation Reporter Optimized for Accurate Measurement of Protein Interactions in Cells
Dixon A, Schwinn M, Hall M, Zimmerman K, Otto P, Lubben T, et al.
ACS Chem Biol
. 2015 Nov;
11(2):400-8.
PMID: 26569370
Protein-fragment complementation assays (PCAs) are widely used for investigating protein interactions. However, the fragments used are structurally compromised and have not been optimized nor thoroughly characterized for accurately assessing these...
8.
Okal A, Mossalam M, Matissek K, Dixon A, Moos P, Lim C
Mol Pharm
. 2013 Aug;
10(10):3922-33.
PMID: 23964676
Because of the dominant negative effect of mutant p53, there has been limited success with wild-type (wt) p53 cancer gene therapy. Therefore, an alternative oligomerization domain for p53 was investigated...
9.
Dixon A, Miller G, Bruno B, Constance J, Woessner D, Fidler T, et al.
Mol Pharm
. 2012 Mar;
9(5):1535.
PMID: 22444272
No abstract available.
10.
Dixon A, Constance J, Tanaka T, Rabbitts T, Lim C
Pharm Res
. 2011 Dec;
29(4):1098-109.
PMID: 22183511
Purpose: Bcr-Abl, the causative agent of chronic myelogenous leukemia (CML), localizes in the cytoplasm where its oncogenic signaling leads to proliferation of cells. If forced into the nucleus Bcr-Abl causes...